US appeals court lifts pause on generic version of Novartis' Entresto
Portfolio Pulse from
A US appeals court has lifted a temporary pause, allowing MSN Pharmaceuticals to proceed with launching a generic version of Novartis' heart-failure drug Entresto.
January 16, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The US appeals court decision allows MSN Pharmaceuticals to launch a generic version of Novartis' Entresto, potentially impacting Novartis' market share and revenues from this drug.
The court's decision enables a generic competitor to enter the market, which could reduce Novartis' sales and market share for Entresto, a key product. This is likely to negatively impact Novartis' short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90